Publication Date 01/07/2014         Volume. 6 No. 6   
Information to Pharmacists


From the desk of the editor

Welcome to the July 2014 homepage edition of i2P (Information to Pharmacists) E-Magazine.
At the commencement of 2014 i2P focused on the need for the entire profession of pharmacy and its associated industry supports to undergo a renewal and regeneration.
We are now half-way through this year and it is quite apparent that pharmacy leaders do not yet have a cohesive and clear sense of direction.
Maybe the new initiative by Woolworths to deliver clinical service through young pharmacists and nurses may sharpen their focus.
If not, community pharmacy can look forward to losing a substantial and profitable market share of the clinical services market.
Who would you blame when that happens?
But I have to admit there is some effort, even though the results are but meagre.
In this edition of i2P we focus on the need for research about community pharmacy, the lack of activity from practicing pharmacists and when some research is delivered, a disconnect appears in its interpretation and implementation.

read more
open full screen

Recent Comments

Click here to read...

Major NIH grant to strike down superbugs

Staff Writer

articles by this author...

Editing and Researching news and stories about global and local Pharmacy Issues

Professor Roger Nation, Dr Kade Roberts, Dr Tony Velkov and Associate Professor Jian Li. Associate Professor Phil Thompson is also part of the MIPS research team.
Doctors treating infectious disease who are down to the last line of defence against antibiotic-resistant superbugs will be buoyed by an A$4.48 million investment in designing new treatments and therapies.
Awarded by the National Institutes of Health (NIH) in the US, the grant will support researchers from the Monash Institute of Pharmaceutical Sciences (MIPS) and Rempex Pharmaceuticals in California to design and develop new antibiotics that are effective against bacterial ‘superbugs’ that cause life-threatening infections and are resistant to all current antibiotics.


The NIH has been a major funder of this innovative research program as this new grant is the third, large RO1 grant received over the last five years.

Antibiotic resistance is an urgent global medical challenge. Currently, a class of antibiotics known as polymyxins are used to treat multidrug-resistant bacteria. However infections that are unresponsive to this last-line therapy have recently been reported in many countries.

The MIPS team comprises Associate Professor Jian Li, Dr Tony Velkov, Professor Roger Nation, Associate Professor Philip Thompson and Dr Kade Roberts. Associate Professor Li and Professor Nation have been investigating polymyxins for more than a decade and are regarded as international leaders in the field.

Rempex is a San Diego based pharmaceutical company focused exclusively on developing drugs to combat emerging antibiotic resistance.

Dr Li, the Program Director of the project, said timing was critical as rising resistance to polymyxins would mean virtually a complete lack of treatment options for some life-threatening infections.

"It is not an exaggeration to state that the world is on the brink of a return to the pre-antibiotic era," Associate Professor Li said.

"In recent decades, bacteria that are resistant to all available antibiotics have emerged, while at the same time there has been a marked decline in the search for new drugs to combat these superbugs."

The five year project will design and develop new antibiotics to address bacterial resistance, and allow successful treatment of acute and chronic infections.

"We're aiming to develop at least one new drug candidate for future clinical trials," Associate Professor Li said.

Senior Vice-President for Research and Development and Chief Scientific Officer at Rempex Michael Dudley Pharm. D, said that industry-academic partnerships would be a very important mechanism for developing new antiinfectives for development.

“Rempex is looking forward to working with the MIPS team on identifying new drug candidates to meet the serious challenge of antibiotic resistance," Dr Dudley said.

The Infectious Diseases Society of America has identified a 'hit-list' of six multidrug-resistant bacteria as being the most difficult to treat. These bacteria will be targeted by the MIPS researchers and their Rempex collaborators in California.


Return to home

Post new comment

The content of this field is kept private and will not be shown publicly.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Allowed HTML tags: <a> <em> <strong> <cite> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Lines and paragraphs break automatically.

More information about formatting options

This question is for testing whether you are a genuine visitor, to prevent automated spam submissions.
Incorrect please try again
Enter the words above: Enter the numbers you hear:

Clinical Newsfeed

health news headlines provided courtesy of Medical News Today.

Click here to

If any difficulty is found in subscribing, please use the "Contact Us" panel found in the navigation bar with the message "subscribe" and your email address.

Subscribe to our mailing list

Email Format


  • Copyright (C) 2000-2015 Computachem Services, All Rights Reserved.

Website by Ablecode